Bayer Cash on Hand 2010-2024 | BAYRY

Bayer cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Bayer cash on hand for the quarter ending September 30, 2024 was $6.970B, a 31.18% decline year-over-year.
  • Bayer cash on hand for 2023 was $11.627B, a 6.33% increase from 2022.
  • Bayer cash on hand for 2022 was $10.935B, a 16.91% increase from 2021.
  • Bayer cash on hand for 2021 was $9.354B, a 32.5% decline from 2020.
Bayer Annual Cash on Hand
(Millions of US $)
2023 $11,627
2022 $10,935
2021 $9,354
2020 $13,857
2019 $6,172
2018 $6,162
2017 $12,558
2016 $9,045
2015 $2,904
2014 $3,424
2013 $3,242
2012 $3,281
2011 $2,465
2010 $3,771
2009 $3,800
Bayer Quarterly Cash on Hand
(Millions of US $)
2024-09-30 $6,970
2024-06-30 $10,795
2024-03-31 $9,687
2023-12-31 $11,627
2023-09-30 $10,129
2023-06-30 $8,320
2023-03-31 $8,560
2022-12-31 $10,935
2022-09-30 $9,139
2022-06-30 $8,720
2022-03-31 $9,195
2021-12-31 $9,354
2021-09-30 $9,692
2021-06-30 $7,829
2021-03-31 $11,227
2020-12-31 $13,857
2020-09-30 $18,166
2020-06-30 $6,285
2020-03-31 $5,572
2019-12-31 $6,172
2019-09-30 $6,176
2019-06-30 $4,734
2019-03-31 $5,581
2018-12-31 $6,162
2018-09-30 $7,498
2018-06-30 $7,796
2018-03-31 $15,546
2017-12-31 $12,558
2017-09-30 $3,992
2017-06-30 $11,006
2017-03-31 $4,372
2016-12-31 $9,045
2016-09-30 $3,791
2016-06-30 $2,223
2016-03-31 $4,525
2015-12-31 $2,904
2015-09-30 $4,380
2015-06-30 $4,494
2015-03-31 $2,771
2014-12-31 $3,424
2014-09-30 $8,225
2014-06-30 $2,531
2014-03-31 $4,688
2013-12-31 $3,242
2013-09-30 $3,121
2013-06-30 $3,228
2013-03-31 $2,784
2012-12-31 $3,281
2012-09-30 $3,744
2012-06-30 $2,555
2012-03-31 $6,160
2011-12-31 $2,465
2011-09-30 $1,672
2011-06-30 $2,586
2011-03-31 $3,672
2010-12-31 $3,771
2010-09-30 $2,740
2010-06-30 $3,255
2010-03-31 $4,214
2009-12-31 $3,800
2009-09-30 $3,709
2009-06-30 $2,498
2009-03-31 $5,709
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $19.295B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $728.847B 75.49
Novo Nordisk (NVO) Denmark $381.440B 27.51
Johnson & Johnson (JNJ) United States $347.829B 14.11
AbbVie (ABBV) United States $310.275B 16.33
Merck (MRK) United States $248.031B 16.48
AstraZeneca (AZN) United Kingdom $202.626B 17.24
Novartis AG (NVS) Switzerland $198.493B 13.19
Pfizer (PFE) United States $149.382B 10.22
Sanofi (SNY) $121.080B 10.97
Innoviva (INVA) United States $1.117B 9.29